Director/PDMR Shareholding

RNS Number : 8022J

Hikma Pharmaceuticals Plc

09 April 2015

 



Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 10 April 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 10 April 2015 at a price of 1,981 pence per Ordinary Share (being the average price for the 30 day period prior to 31 December 2014, in accordance with the EIP rules) as follows:

PDMR	Element B Shares	Element C Shares
Bassam Kanaan	19,945	19,945
Michael Raya	19,655	19,655
Khalid Nabilsi	14,165	14,165
Riad Mishlawi	13,811	13,811
Susan Ringdal	12,012	12,012
Majda Labadi	10,089	10,089

The Element B share awards will be released to the participants in two years' time subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.

The Element C share awards will be released to the participants in three years' time subject to their continued employment.

These participants are not allowed to sell 50% of the vested shares under elements B and C until five years.

Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC         

Peter Speirs                                                                       [phone]

Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

 

END

 

 

RDSBCGDSXBGBGUC